# A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization

> **NCT06503250** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 113 (actual)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **RADIATION:** Transarterial Chemoembolization

## Key facts

- **NCT ID:** NCT06503250
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-19
- **Primary completion:** 2024-11-27
- **Final completion:** 2024-11-27
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503250, "A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06503250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*